Sanofi SA has signed a new licensing agreement with Exscientia Plc, a UK drug discovery firm, to tap its expertise in artificial intelligence for the development of up to 15 small molecule drug candidates in the fields of oncology and immunology.
The two companies have been working together since 2016 and in 2019, Sanofi in-licensed a bispecific small molecule directed against two targets in inflammation and immunology.